Evidence map›Paper›PMID 33587652›Full record

Trial reportClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.

Yongqiang Zhao, Yu Hu, Jie Jin, Xielan Zhao, Xuefeng Wang, Runhui Wu, Depei Wu, Renchi Yang, Feng'e Yang, Qun Hu and 3 more

Open access · goldAbstract readClinical Trial, Phase IVComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 2 countries.

Yongqiang ZhaoPeking Union Medical College Hospital, Beijing, China.
Yu HuUnion Hospital, 66375Tongji Medical College of Huazhong, Wuhan, China.
Jie JinThe First Affiliated Hospital of College of Medicine, 12377Zhejiang University, Hangzhou, China.
Xielan Zhao159374Xiangya Hospital, Central South University, Changsha, China.
Xuefeng Wang162762Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Runhui Wu117984Beijing Children's Hospital, Capital University of Medical Sciences, Beijing, China.
Depei Wu74566The First Affiliated Hospital of Soochow University, Soochow, China.
Renchi YangBlood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
Feng'e Yang117890Fujian Medical University Union Hospital, Fuzhou, China.
Qun Hu66375Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Juan WangCangzhou Central Hospital, Cangzhou, China.
Hai FangShire BioScience (Shanghai) Co., Ltd., a Takeda Company, Shanghai, China.ORCID https://orcid.org/0000-0002-8130-6161
Werner EnglBaxalta Innovations GmbH, a Takeda Company, Vienna, Austria.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing Children’s Hospital · CNCangzhou Central Hospital · CNCentral South University · CNFirst Affiliated Hospital Zhejiang University · CNFujian Medical University · CNShanghai Jiao Tong University · CNSoochow University · CNTakeda (Austria) · ATTongji Hospital · CNWuhan Union Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antihemophilic factor (recombinant) (rAHF; ADVATE

Indexed as

AdolescentAdultChildChild, PreschoolChinaCoagulantsDrug Administration ScheduleFactor VIIIHemophilia AHemorrhageHumansInfantMaleMiddle AgedProduct Surveillance, PostmarketingProspective StudiesCoagulantsF8 protein, humanFactor VIIIRecombinant ProteinsChinahemophilia Aon-demandpostmarketing product surveillanceprophylaxisrecombinant factor VIII

Identifiers

PMID33587652
PMCPMC7890741
OpenAlexW3132953843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.